Publications by authors named "Nadine A Kahle"
Importance: Choroideremia (CHM) is a rare, degenerative, genetic retinal disorder resulting from mutation of the CHM gene, leading to an absence of functional ras-associated binding escort protein 1 (REP1). There is currently no approved treatment for CHM.
Objective: To assess the safety and efficacy of retinal gene therapy with an adeno-associated virus vector (AAV2) designed to deliver a functional version of the CHM gene (AAV2-REP1) for treatment of patients with choroideremia.
Purpose: Choroideremia (CHM) is a rare inherited retinal degeneration resulting from mutation of the CHM gene, which results in absence of functional Rab escort protein 1 (REP1). We evaluated retinal gene therapy with an adeno-associated virus vector that used to deliver a functional version of the CHM gene (AAV2-REP1).
Methods: THOR (NCT02671539) is a Phase 2, open-label, single-center, randomized study.
Article Synopsis
- * In a clinical study, patients received a single subretinal injection of a gene therapy (rAAV.hCNGA3) aimed at restoring the function of these cone photoreceptors.
- * The study primarily evaluated the safety of this treatment through a series of eight visits in the first year and annual follow-ups over four years, using specialized methods to assess outcomes.
Bacteria communicate with one another via specialized signaling molecules, known as quorum sensing molecules or autoinducers. The Pseudomonas aeruginosa-derived quorum sensing molecule N-(3-oxododecanoyl)-l-homoserine lactone (AHL-12), however, also activates mammalian cells. As shown previously, AHL-12-induced chemotaxis, up-regulated CD11b expression, and enhanced phagocytosis of polymorphonuclear neutrophils.
View Article and Find Full Text PDF